Background: Identifying comorbidities that influence preclinical Alzheimer's disease (AD) can give some insight into the AD early stages trajectories to allow new treatment venues and to guide public health systems to prevent subsequent dementia. Objective: To examine the association of multimorbidity with AD neuroimaging markers in cognitively normal older adults. Methods: This study had a cross-sectional design. Data regarding 14 comorbidities were obtained for all 318 adults aged 70-85 years, recruited from the community to an ongoing prospective monocentric cohort. They underwent standardized neuropsychological and neuroimaging assessment with automated methods that measured hippocampal volumes, white matter hyperintensity volumes, fluorodeoxyglucose positron emission tomography (FDG-PET) standardized uptake values (SUV) in AD signature regions, and amyloid positron emission tomography (amyloid-PET) SUV ratios. Linear regression was used to assess the association of multimorbidity with AD neuroimaging biomarkers. Results: Multimorbidity is signif- icantly associated with lower hippocampal volumes (-0.03 ± 0.01; p = 0.012; R 2 = 0.017) and lower FDG-PET SUV (-0.027 ± 0.009; p = 0.005; R 2 = 0.022), with no association with amyloid deposition (0.001 ± 0.007; p = 0.884; R 2 = 0.0001). Taken individually, obesity and excessive alcohol use are associated with lower FDG-PET values, whereas obstructive sleep apnea and mood disorders are related to lower amyloid-PET SUV ratios. Conclusion: Multimorbidity is associated with preclinical AD imaging markers of neurodegeneration, but not with amyloid.
Introduction
Several acquired comorbidities have been described to increase the risk of developing dementia or Alzheimer's disease (AD) [1] . Most of them are conditions that are modifiable with treatment, such as hypertension, dyslipidemia, or diabetes [2] . The co-occurrence of multiple chronic conditions (≥2 diseases) characterizes multimorbidity, an entity whose prevalence rises with age [3] , affecting more than half of the older adult population. Multimorbidity has been associated with adverse health outcomes such as mild cognitive impairment [4] , diminished quality of life, functional limitation, frailty, and mortality [5] . Many of these chronic conditions commonly observed in multimorbidity are also established risk factors for AD. Moreover, they can directly impact brain neurogenesis by different underlying mechanisms, influencing for example the size of the hippocampus towards lower volumes throughout life [6] .
This study aimed to examine whether various AD neuroimaging biomarkers of neurodegeneration and amyloid deposition are related to multimorbidity in cognitively normal older adults. We hypothesized that different disease clusters create different illness burden, so that the type, number, and severity of comorbidities may modulate the rate of atrophy and metabolism decline, being at least one important variable in a complex model of factors determining the extent of preclinical AD stage.
In the scope of recent failures of targeted drug trials against AD [7] , the identification of treatable conditions that raise the risk of preclinical AD might (1) play a role in future trials as enrichment factors at inclusion, (2) give some mechanistic insight into the early stage of AD to allow new treatment venues, and (3) guide public health strategy to prevent subsequent dementia.
Methods

Study Population
The INSIGHT-PreAD is an ongoing prospective monocentric cohort with the objective to determine factors that increase the risk of progression to clinical AD of cognitively normal older adults. INSIGHT-PreAD enrolled participants aged 70-85 years, with a subjective cognitive decline and no objective cognitive disorders defined by a Mini-Mental State Examination score ≥27 and a total recall score in the Free and Cued Selective Reminding Test ≥41 [8] . The exclusion criteria included a Clinical Dementia Rating Scale score > 0 [9] , visual and auditory functions insufficient for neuropsychological testing, existence of a known neurological disease, recent stroke, and illiteracy.
Clinical Data
Demographic data were obtained at baseline and a comorbidity profile was established based on selfreported diagnosis during the standardized clinical follow-up. The presence of 14 chronic conditions was assessed: hypertension, dyslipidemia, diabetes mellitus, atrial fibrillation, heart failure, chronic kidney disease, obstructive sleep apnea (OSA), active or past smoking, unhealthy alcohol consumption, prior head trauma, obesity, vitamin B 12 deficiency, depression, and post-traumatic stress disorder. Diagnoses were vali-dated by a physician (A.M.) according to standardized criteria from the International Classification of Diseases (10th revision). Data regarding chronic kidney failure was not available for 23 subjects.
Obesity was defined as body mass index ≥30 according to the World Health Organization definition. All participants were assessed for height and weight at baseline. Similarly, blood samples were obtained in the morning and serum vitamin B 12 was analyzed by the electrochemiluminescence immunoassay method. Vitamin B 12 deficiency was defined as a concentration < 125 pg/mL.
Regarding mood disorders, we considered the diagnosis present for both early-and late-onset episodes as well as recurrent disorders.
All head trauma episodes were recorded independent of severity. As a limitation of self-reported conditions, we were not able to specify criteria for traumatic brain injury [10] . Excessive alcohol consumption was defined according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria. The choice of these chronic conditions represents potentially modifiable risk factors for dementia, treatment of or intervention for which could possibly delay or prevent new dementia cases [11] .
Neuroimaging Assessment: Hippocampal Volumetry All participants underwent MRI at baseline in the same Siemens Magnetom Verio 3T scanner. Hippocampal segmentation was performed using a fully automated method developed in-house, based on simultaneous region deformation driven by both anatomical and probabilistic priors [12] . Anatomical information was derived from local anatomical patterns that are stable in controls and AD patients, around landmarks automatically detected during the deformation. Probabilistic information was derived from an atlas built from the registration of manually segmented hippocampi from 16 young healthy subjects. Initialization was obtained from global information and deformation was constrained by local anatomical and probabilistic information. Volumes were normalized by total intracranial volume [13] .
Neuroimaging Assessment: White Matter Hyperintensity (WMH) Volumetry
Automated volumetry of white matter hyperintensity was obtained from all participants using the WMH Automated Segmentation Algorithm (WHASA) method and expressed in cm 3 . The WHASA relies on increased contrast between WMH and surrounding tissues by extracting tissue information from T1 images, registering it to the FLAIR image and correcting for intensity inhomogeneities [14] . The nonlinear diffusion framework enables then to enhance the contrast of WMH on the FLAIR image and to obtain a piecewise constant image. Processing of PET Images. The Centre pour l'Acquisition et le Traitement des Images developed a pipeline allowing quantification of radiotracer uptake in the grey matter of untransformed PET images, with high throughput and a step-by-step quality check. The aim was to reduce quantification biases related to spatial normalization, coregistration, and partial volume effect. MRI 3D T1-weighted images were segmented and spatially normalized into the MNI space using the VBM8 package implemented in SPM8 [15] . Deformation fields as well as grey and white matter masks were generated and further used to define regions of interest (ROIs). Structural MRI images were coregistered to PET images using SPM8 with visual inspection to detect any coregistration errors. Using inverse deformation fields and matrix transformation, composite cortical ROIs and a reference region were placed in the individual native PET space. After correcting for partial volume effect with the RBV-sGTM method [16] , parametric PET images were created for each individual by dividing each voxel with the mean activity extracted from the reference region.
PET Variables. Metabolic indexes were calculated in ROIs involving AD-specific regions such as right and left precuneus, posterior cingulate cortex, associative parietal and temporal cortex, and hippocampus, as well as ROIs in the frontal and occipital cortex [17] . The reference region was the pons. For amyloid-PET images, SUV ratios were calculated by averaging the mean activity of cortical ROIs: both left and right precuneus, cingulum posterior, cingulum anterior, as well as parietal, temporal, and orbitofrontal cortex. The reference region was a combination of whole cerebellum and pons regions [18] .
Statistical Analysis
Descriptive data of the population are expressed as number of cases and proportions for categorical variables and as means and standard deviations (SDs) for continuous variables. Differences between men and women were assessed by Fisher's exact test or Student's t test if variables were categorical or continuous, respectively.
The associations between the accumulation of comorbidities and their effect as individual conditions with the AD neuroimaging biomarkers were assessed by linear regression methods. For this purpose, hippocampal volumes, metabolic indexes, and amyloid-PET SUV ratios were analyzed as continuous variables in our models.
We predetermined five possible confounding factors for adjustments in the multivariate analysis: age, sex, educational level, ApoE4 status, and WMH volumes. We performed linear regression univariate analysis to evaluate their association to neuroimaging variables. Variables presenting statistically significant associations were used as adjustment factors in the multivariate linear regression model for comorbidity, applied to their respective neuroimaging biomarker.
Results were considered significant at p < 0.05 and all statistical analyses were performed using the SAS software (version 9.4; SAS Institute, Cary, NC, USA). Values are presented as mean ± SD or n (%). Fisher's exact test was used for categorical variables and Student's t test for continuous variables. Level of education was assessed by a scale from 1 (no formal education) to 8 (at least 2 years after high school graduation). PTSD, post-traumatic stress disorder.
Results
Population Characteristics
The cohort of 318 cognitively normal subjects was composed of 204 (64.2%) women, with a global mean age of 76 years (SD: 3). They had a high mean sociocultural level of 6 (SD: 2) on a scale from 1 (no formal education) to 8 (at least 2 years after high school graduation). Hypertension, dyslipidemia, mood disorders, and chronic kidney failure were the most commonly observed comorbidities, and 70% of participants had at least two chronic conditions (Table 1) . Mood disorders were more prevalent in women, whereas hypertension, heart failure, OSA, and tobacco use were significantly more prevalent in men. There were no differences regarding ApoE4 allele prevalence.
Adjustment Factors and Neuroimaging Biomarkers
Age influenced the three biomarkers studied, while female sex was associated with higher normalized hippocampal volumes and FDG-PET, with no significant interaction with amyloid-PET SUV ratios ( Table 2 ). The higher comorbidity burden observed in men can partly explain these differences. Linear regression univariate analysis. Level of education was assessed by a scale from 1 (no formal education) to 8 (at least 2 years after high school graduation). AD, Alzheimer's disease; FDG-PET, fluorodeoxyglucose positron emission tomography; PET, positron emission tomography; SUV, standardized uptake value; WMH, white matter hyperintensity. While ApoE4 status was not associated with FDG-PET indexes, a trend toward significance was observed in the association of positive ApoE4 status and lower hippocampal volumes. Interestingly, WMH was not associated with hippocampal volumes or FDG-PET indexes; however, higher WMH volumes were significantly associated with higher SUV ratios in amyloid-PET (Fig. 1) .
Multimorbidity and Neuroimaging Biomarkers
The increasing number of comorbidities was significantly associated with lower hippocampal volumes (-0.03 ± 0.01; p = 0.012; R 2 = 0.017) as well as with lower SUV (-0.027 ± 0.009; p = 0.005; R 2 = 0.022) in FDG-PET. On the other hand, we did not observe any association between comorbidities accumulation and SUV ratios in amyloid-PET (0.001 ± 0.007; p = 0.884; R 2 = 0.0001). After adjustment for possible confounding factors, the association remained statistically significant only for FDG-PET SUV (-0.02 ± 0.01; p = 0.038; R 2 = 0.07). Both obesity and excessive alcohol use were associated with lower metabolism in FDG-PET in the univariate and multivariate models. Moreover, smoking presented a statically significant association with lower hippocampal volumes, but no significant association was observed after adjustment for possible confounding factors (Table 3) . Linear regression models in univariate and multivariate analysis; results expressed as parameter estimate ± standard error. As for the adjustment factors, significant associations in univariate analysis realized for five predetermined factors (age, sex, education level, ApoE4 status, and WMH volume) were incorporated in each model of AD neuroimaging biomarker. Individual comorbidities not shown in the table did not have a statistically significant association (p < 0.05) in the univariate model. AD, Alzheimer's disease; FDG-PET, fluorodeoxyglucose positron emission tomography; PET, positron emission tomography; SUV, standardized uptake value; WMH, white matter hyperintensity.
Increased amyloid-PET SUV ratio was associated with the presence of dyslipidemia in the univariate linear regression model (0.048 ± 0.022; p = 0.029; R 2 = 0.047). Surprisingly, OSA and mood disorders were inversely associated with amyloid-PET SUV ratio, remaining statistically significant after adjustment for possible confounding factors (Table 3) .
Discussion
In this study with 318 cognitively normal older adults, we observed that the accumulation of multiple chronic conditions, i.e. multimorbidity, is associated with neuroimaging markers of AD neurodegeneration, but not with amyloid deposition.
Some of the multiple chronic conditions explored in our study were singularly associated with lower hippocampal volumes and lower metabolism in AD-specific brain regions. The lower metabolism in FDG-PET AD signature regions was independent of ApoE4 status. These results are in agreement with those of a previous study regarding 1,449 cognitively normal subjects, in which the investigators observed an association of multimorbidity with FDG-PET hypometabolism and abnormal AD signature cortical thickness, whereas these were unrelated to amyloid [19] . Our study demonstrates comparable results with a different spectrum of comorbidities, adding information regarding the association with hippocampal atrophy not yet assessed. Besides that, by using a linear regression statistical approach, we could establish associations without determining normal/abnormal cutoff values in neuroimaging variables, showing that the association of comorbidities with neurodegeneration may be part of a continuum [20, 21] . Interactions among vascular risk factors, frequently observed as comorbidities in older adults, are probably implicated in this pathophysiology [22, 23] . Multimorbidity has been recognized as an entity by itself, exceeding the simple coexistence of multiple chronic conditions [24] . It has been demonstrated that their interactions transcend a merely additive effect, presenting a more complex synergism regarding vascular burden for example, but also other pathophysiological processes such as inflammation and oxidative stress [25] . Our hypothesis is that different disease clusters create different illness burden and may impact neurodegeneration in a unique manner [26] . Therefore, the type, number, and severity of comorbidities may modulate the rate of atrophy and metabolism decline, being at least one important variable in a complex model of factors determining the extent of preclinical AD stage. Surprisingly, we did not observe a relationship between lower hippocampal volumes and vascular risk factors, classically related to a negative impact on hippocampus neurogenesis. This may be explained by our small sample size.
We observed that active or past smoking was associated with lower hippocampal volumes. It has been demonstrated that chronic cigarette smoking may negatively impact cognition, including memory, due to oxidative stress-induced lesions [27] . We found that chronic excessive alcohol use was associated with lower metabolism in FDG-PET. Alcohol consumption seems to influence hippocampal neurogenesis as well as brain metabolism [28] . Intoxication states are associated with a switch in metabolism patterns, increasing acetate metabolism and reducing glucose use, as was demonstrated in FDG-PET studies [29] . It is not clear whether these effects may be transitory or permanent in the path towards neurodegeneration.
In this study, obesity was related to lower metabolism in FDG-PET, but not to hippocampal atrophy. Obesity seems to be implicated in neurodegeneration, increasing the risk of cognitive impairment in late life, and has been shown to be associated with decreased brain volumes [30, 31] .
Cigarette smoking, excessive alcohol consumption, and obesity are major public health concerns. Establishing their association with neurodegeneration parameters in the early course of dementia should trigger prompt interventions targeting these risk factors.
In this study, OSA and mood disorders were associated with lower amyloid-PET SUV ratios. However, there is evidence that both comorbidities may be actually associated with increased amyloid deposition. OSA leads to recurrent sleep fragmentation and hypoxia, which upregulates the expression of the amyloid precursor protein, diminishing Aβ clearance from the brain [32] . In animal models, chronic hypoxia enhanced amyloid plaque generation, with a significant decline in memory [33] . Depression is not only an AD risk factor, but can also be an initial phenotype of AD [34] . There is evidence mainly from cross-sectional studies relating mood disorders to amyloid deposition, showing that subjects with major depression have lower cerebrospinal fluid Aβ42 and higher amyloid deposition in PET studies [35, 36] . The discrepancies with our data may be a result of the lack of available information regarding the depression episode (early-life, late-late, or recurrent) as well as the severity of the disease and possible treatments implemented for both comorbidities.
Just as recent data from previous cross-sectional studies, we also found an association between higher WMH volumes and amyloid deposition [37] . WMH is highly prevalent and related to vascular risk factors in older adults, but the possible causal relationship between amyloid and WMH needs further exploration in longitudinal studies. WMH could accelerate amyloid deposition, but amyloid may also affect WMH burden, independently of vascular risk factor treatment.
This study has some limitations. The cross-sectional analyses did not allow us to infer temporality associations between comorbidities and neuroimaging biomarkers. Also, there was a possible selection bias regarding the participants of INSIGHT-PreAD because we excluded participants with severe sensorial deficits at recruitment so that we were able to apply the same neuropsychological assessment to all participants.
Similarly, our participants were highly educated, which could have influenced the prevalence of comorbidities and their medical management. Education can improve personal health behaviors at the individual level, leading to better prevention and lifestyle choices, but it is also related to better access to healthcare and consequent diagnosis of comorbidities.
The main strength of this study lies in its standardized multimodal clinical and neuroimaging acquisition protocols and its monocentric nature, allowing for optimal homogeneity of the cohort. A future longitudinal analysis in multimorbidity may help understand the progression of neurodegeneration and amyloid deposition along with possible causality associations. Various comorbidities may be targeted with adequate treatment, raising the question of how their multimodal assessment and therapies during the early and late adult lifespan could impact preclinical AD trajectories.
